Alloy Therapeutics, a privately held biotechnology ecosystem company based in the United States, and the Institute for Protein Innovation (IPI), a Boston-based nonprofit research organization, announced an antibody discovery collaboration centered on the co-development of synthetic humanized VHH antibody libraries. The partnership, disclosed May 5, 2026, combines Alloy’s integrated drug discovery infrastructure and AI-driven platform ecosystem with IPI’s protein engineering capabilities and in vitro discovery systems. No financial terms were disclosed.
The collaboration is structured around building bespoke nanobody libraries optimized for developability, with intended application across bispecific and multispecific therapeutic formats. IPI has contributed two synthetic, humanized VHH libraries developed using yeast display, engineered to improve stability, reduce immunogenicity, and support plug-and-play integration into complex therapeutic architectures. Alloy contributes in vivo capabilities, scalable platform infrastructure, and access to its broader biotech and pharmaceutical partner network.
No specific drug candidates, molecular targets, disease indications, or clinical programs were identified in the disclosed materials. The collaboration is positioned at the discovery and platform level, with the intent of enabling downstream partner programs rather than advancing a named internal asset.
Platform architecture and the role of VHH antibodies
VHH antibodies, derived from the single-domain heavy-chain antibodies found in camelid species and commonly referred to as nanobodies, occupy a distinct position in the antibody engineering landscape. Their small size relative to conventional immunoglobulins, combined with high thermal stability and the capacity to engage epitopes that are sterically inaccessible to standard antibody formats, has made them a subject of sustained interest in drug development. Their modular structure also makes VHH antibodies particularly suited to construction of bispecific and multispecific molecules, where the ability to combine binding domains without introducing prohibitive steric or stability constraints is a practical advantage.
The libraries contributed by IPI were developed using yeast display, a surface-expression technology that allows high-throughput screening of large synthetic antibody repertoires against target proteins under controlled in vitro conditions. Yeast display enables iterative affinity maturation and selection without the requirement for animal immunization, which is central to IPI’s in vitro discovery model. The synthetic humanized design of the libraries is intended to address developability concerns that have historically complicated the translation of camelid-derived sequences into clinical-stage molecules, including immunogenicity risk and suboptimal biophysical properties.